Table 1 Predicted anti-SARS-CoV-2 compounds in vitro efficacy testing from two independent rounds of testing.

From: Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses

 

Compound

IC50 (μM)

CC50 (μM)

SI index

Round 1

Homoharringtonine

0.16

2.14

12.84

Bortezomib

1.39

 > 50

35.93

Trametinib

14.95

 > 50

3.34

Lacidipine

14.89

20.15

1.35

Dasatinib

19.74

13.20

0.67

Remdesivir

12.08

 > 50

4.14

Chloroquine

12.0

127.8

10.65

Round 2

Ganetespib

35.50

28.95

0.82

Ixazomib

11.71

 > 50

4.27

Tanespimycin

31.33

 > 50

1.60

Bortezomib

3.42

 > 50

14.63

Homoharringtonine

0.26

6.22

24.06

Chloroquine

9.80

 > 150

15.31

Remdesivir

7.45

 > 50

6.71

Lopinavir

13.50

 > 50

3.70

  1. IC50, CC50, and SI index were calculated of each compound in SARS-CoV-2 infected in Vero cells. Homoharringtonine and bortezomib exhibited strong antiviral activities with corresponding cytotoxicity CC50 at least 20 times higher than the viral killing IC50.
Back to article page